Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early‐Stage Squamous Cell Carcinoma of the Head and Neck: Long‐Term Follow‐Up

Documents similaires

• Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
  par: Aarti Bhatia, et autres
  Publié: (2025)
• Correction to “Snail Controls the Mesenchymal Phenotype and Drives Erlotinib Resistance in Oral Epithelial and Head and Neck Squamous Cell Carcinoma Cells”
  Publié: (2024)
• Examining the Interaction Between Sex and Race in Outcomes of Head and Neck Squamous Cell Carcinoma
  par: Geena Jung, et autres
  Publié: (2025)
• Efficacy of Multimodal Work‐Up of Head and Neck Squamous Cell Carcinoma Lymph Node Metastasis of Unknown Primary
  par: Robin W. Jansen, et autres
  Publié: (2025)
• Aggressive Head and Neck Squamous Cell Carcinoma in the Setting of GATA2 Deficiency
  par: Brejjette Aljabi, et autres
  Publié: (2025)